Skip to main content

Table 3 Synopsis of baseline characteristics and clinical outcomes of patients with NNRTI PDR

From: Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi

NoBaseline characteristicsClinical outcomes
ART start dateAgeSexWHO stageCD4 countViral loadNNRTI DRMVL 6moLast known VLTreatment outcomeLast known ART regimenStatus date
113.10.201436Female149317,539K103N63627,000AliveOnART3TC/ZDV/ATV/r31.10.2019
207.10.201441Female2na84,598K103N, V106M4040AliveOnART3TC/TDF/EFV31.10.2019
313.11.201425Female2na86,861Y181C110,384110,384Defaulted3TC/TDF/EFV07.10.2015
411.09.201446Female156naK103N4040AliveOnART3TC/TDF/DTG31.10.2019
517.09.201442Male21235765V108I, Y181C, H221Y, M184V40489AliveOnART3TC/TDF/DTG31.10.2019
608.10.201436Female316224,736K103N, V138Q, Y181Cna224,736Died3TC/TDF/EFV27.01.2015
713.10.201432Female19237,507V179Dna150Defaulted3TC/TDF/EFV08.06.2017
814.10.201451Male1na377,623E138Kna377,623Defaulted3TC/TDF/EFV12.01.2015
905.11.201433Female3na121,761K103Nna121,761Died3TC/TDF/EFV06.12.2014
1011.11.201442Male138035,529V108I, Y181C, H221Y4040AliveOnART3TC/TDF/EFV31.10.2019
1120.11.201460Male349800,810Y181C, H221Y4040Defaulted3TC/ZDV/ATV/r10.09.2019
1202.12.201431Male12948117K103N4040Defaulted3TC/TDF/EFV11.03.2016
1315.05.201532Female147716,293K238T4040AliveOnART3TC/TDF/DTG31.10.2019
1406.05.201525Female145614,946K103N, A98G, V108I4040Defaulted3TC/TDF/EFV22.12.2018
1528.05.201523Female24061,824,545K103N4040Defaulted3TC/TDF/EFV17.04.2017
1611.05.201540Female116345,245E138G4040AliveOnART3TC/TDF/DTG31.10.2019
1710.11.201429Female2183708,905V108I, Y181C, H221Yna708,905TransferOut3TC/TDF/EFV13.05.2015
1818.05.201534Female144204,902E138G7936150Defaulted3TC/ZDV/ATV/r27.05.2018
1921.05.201522Female187243,509V106M, V179Dna243,509Defaulted3TC/TDF/EFV16.09.2015
2020.05.201528Female3na329,391G190Ana40TransferOut3TC/TDF/EFV19.03.2017
2122.05.201530Male1376507,147K103N4040AliveOnART3TC/TDF/DTG31.10.2019
2228.05.201529Female12302,091,728A98G, E138A40150AliveOnART3TC/TDF/DTG31.10.2019
2327.05.201525Female14111,546,355K103S, G190A4040Defaulted3TC/TDF/EFV01.09.2019
2401.06.201526Female1209990,009K103Nna990,009Defaulted3TC/TDF/EFV03.11.2015
2504.06.201543Male1294529,513Y181Cna40AliveOnART3TC/TDF/DTG31.10.2019
2623.06.201528Female1484naK101E, E138A4040AliveOnART3TC/TDF/DTG31.10.2019
2719.06.201545Female4179naK103N, A98GnanaDefaulted3TC/TDF/EFV22.05.2016
  1. No Patient number, ART Antiretroviral therapy, WHO stage World Health Organization stage of clinical HIV illness, CD4 count Number of CD-4 positive T-cells per µl, VL Viral Load, Number of copies of HIV-1 RNA per ml of Serum, NNRTI Non-nucleoside reverse-transcriptase inhibitor, DRM Drug resistance mutations, EFV Efavirenz, 3TC Lamivudine, TDF Tenofovir disoproxil fumarate, ZDV Zidovudine, ATV/r Atazanavir + Ritonavir, DTG Dolutegravir